Maggie Stanislawski
Concepts (505)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 9 | 2025 | 716 | 2.520 |
Why?
| | Microbiota | 9 | 2026 | 753 | 1.770 |
Why?
| | Obesity | 11 | 2025 | 3007 | 1.240 |
Why?
| | Body Mass Index | 10 | 2025 | 2390 | 1.120 |
Why?
| | Life Style | 1 | 2025 | 479 | 0.760 |
Why?
| | Percutaneous Coronary Intervention | 11 | 2020 | 489 | 0.750 |
Why?
| | United States Department of Veterans Affairs | 14 | 2020 | 711 | 0.730 |
Why?
| | Behavior Therapy | 2 | 2021 | 282 | 0.720 |
Why?
| | Fatty Liver | 2 | 2021 | 237 | 0.680 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 88 | 0.660 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 360 | 0.590 |
Why?
| | Weight Loss | 2 | 2021 | 794 | 0.590 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 2529 | 0.590 |
Why?
| | Feces | 5 | 2025 | 489 | 0.580 |
Why?
| | Biostatistics | 1 | 2018 | 18 | 0.570 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2025 | 2122 | 0.530 |
Why?
| | Coronary Artery Disease | 6 | 2023 | 716 | 0.530 |
Why?
| | Pacemaker, Artificial | 4 | 2020 | 121 | 0.520 |
Why?
| | Weight Gain | 2 | 2018 | 536 | 0.520 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 196 | 0.500 |
Why?
| | Insulin Resistance | 3 | 2024 | 1221 | 0.490 |
Why?
| | Bacteria | 3 | 2020 | 872 | 0.470 |
Why?
| | Glucose Oxidase | 7 | 1994 | 25 | 0.450 |
Why?
| | Phylogeny | 2 | 2018 | 997 | 0.450 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 263 | 0.450 |
Why?
| | Pediatric Obesity | 2 | 2019 | 604 | 0.440 |
Why?
| | Prosthesis-Related Infections | 4 | 2020 | 98 | 0.430 |
Why?
| | Risk Factors | 16 | 2025 | 10490 | 0.430 |
Why?
| | Liver | 9 | 2020 | 1821 | 0.420 |
Why?
| | Antibiotic Prophylaxis | 3 | 2020 | 122 | 0.420 |
Why?
| | RNA, Ribosomal, 16S | 5 | 2018 | 542 | 0.410 |
Why?
| | Asthma | 1 | 2025 | 1911 | 0.400 |
Why?
| | Veterans Health | 4 | 2018 | 186 | 0.400 |
Why?
| | Phenotype | 6 | 2023 | 3172 | 0.390 |
Why?
| | Female | 48 | 2025 | 75814 | 0.390 |
Why?
| | Middle Aged | 31 | 2025 | 34658 | 0.390 |
Why?
| | Humans | 61 | 2026 | 141284 | 0.380 |
Why?
| | Lactoperoxidase | 7 | 1994 | 7 | 0.380 |
Why?
| | Male | 41 | 2025 | 70140 | 0.370 |
Why?
| | Peroxidases | 5 | 1993 | 29 | 0.340 |
Why?
| | Coronary Artery Bypass | 4 | 2017 | 251 | 0.330 |
Why?
| | Pregnancy | 7 | 2021 | 7035 | 0.320 |
Why?
| | Immunotoxins | 4 | 1990 | 55 | 0.310 |
Why?
| | Aged | 25 | 2025 | 24836 | 0.300 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2091 | 0.290 |
Why?
| | Dextrans | 5 | 1988 | 85 | 0.290 |
Why?
| | Veterans | 7 | 2018 | 1519 | 0.290 |
Why?
| | Immunoglobulin Idiotypes | 7 | 1988 | 28 | 0.280 |
Why?
| | Bifidobacterium | 2 | 2017 | 21 | 0.270 |
Why?
| | Myocardial Infarction | 6 | 2018 | 1066 | 0.270 |
Why?
| | Cohort Studies | 7 | 2025 | 5809 | 0.260 |
Why?
| | United States | 21 | 2025 | 15298 | 0.260 |
Why?
| | Multifactorial Inheritance | 2 | 2025 | 179 | 0.260 |
Why?
| | Coronary Angiography | 7 | 2020 | 316 | 0.260 |
Why?
| | Adult | 12 | 2025 | 39319 | 0.250 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 240 | 0.230 |
Why?
| | Radial Artery | 2 | 2017 | 69 | 0.220 |
Why?
| | Defibrillators, Implantable | 2 | 2020 | 318 | 0.220 |
Why?
| | Time Factors | 11 | 2021 | 6951 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 543 | 0.220 |
Why?
| | Genome-Wide Association Study | 4 | 2025 | 1408 | 0.210 |
Why?
| | Diet | 3 | 2023 | 1277 | 0.210 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5653 | 0.210 |
Why?
| | HIV-1 | 3 | 1995 | 882 | 0.210 |
Why?
| | T-Lymphocytes | 8 | 1995 | 1996 | 0.210 |
Why?
| | Longevity | 1 | 2025 | 174 | 0.210 |
Why?
| | Risk Assessment | 4 | 2021 | 3522 | 0.200 |
Why?
| | Logistic Models | 3 | 2025 | 2098 | 0.200 |
Why?
| | Child | 6 | 2021 | 22390 | 0.200 |
Why?
| | Registries | 3 | 2019 | 2205 | 0.190 |
Why?
| | Plasmacytoma | 8 | 1989 | 19 | 0.190 |
Why?
| | Age Factors | 2 | 2021 | 3295 | 0.190 |
Why?
| | Machine Learning | 2 | 2026 | 555 | 0.190 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2020 | 626 | 0.180 |
Why?
| | Metagenomics | 1 | 2023 | 180 | 0.180 |
Why?
| | Norway | 2 | 2018 | 44 | 0.180 |
Why?
| | Patient Identification Systems | 2 | 2019 | 16 | 0.180 |
Why?
| | Electronic Health Records | 2 | 2020 | 1129 | 0.180 |
Why?
| | Mothers | 2 | 2018 | 776 | 0.180 |
Why?
| | Acute Kidney Injury | 2 | 2020 | 822 | 0.180 |
Why?
| | Mississippi | 1 | 2021 | 21 | 0.180 |
Why?
| | Proton Therapy | 1 | 2021 | 14 | 0.170 |
Why?
| | Waist Circumference | 1 | 2021 | 134 | 0.170 |
Why?
| | Diet, Reducing | 1 | 2021 | 90 | 0.170 |
Why?
| | Incidence | 4 | 2021 | 2809 | 0.170 |
Why?
| | Computational Biology | 1 | 2026 | 663 | 0.170 |
Why?
| | Adiposity | 1 | 2025 | 520 | 0.160 |
Why?
| | Software | 1 | 2026 | 675 | 0.160 |
Why?
| | Gardening | 1 | 2020 | 13 | 0.160 |
Why?
| | DNA, Bacterial | 2 | 2018 | 333 | 0.160 |
Why?
| | Caloric Restriction | 1 | 2021 | 125 | 0.160 |
Why?
| | Weight Reduction Programs | 1 | 2021 | 117 | 0.160 |
Why?
| | Mice, Inbred BALB C | 14 | 1989 | 1261 | 0.160 |
Why?
| | Western World | 1 | 2019 | 7 | 0.150 |
Why?
| | Fasting | 1 | 2021 | 283 | 0.150 |
Why?
| | Atherosclerosis | 1 | 2023 | 402 | 0.150 |
Why?
| | Precision Medicine | 1 | 2023 | 435 | 0.150 |
Why?
| | Cardiac Catheterization | 3 | 2018 | 543 | 0.150 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 16 | 0.150 |
Why?
| | Fluid Therapy | 1 | 2020 | 143 | 0.150 |
Why?
| | Proportional Hazards Models | 6 | 2018 | 1268 | 0.150 |
Why?
| | Adolescent | 5 | 2021 | 22116 | 0.140 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.140 |
Why?
| | Drug Users | 1 | 2018 | 42 | 0.140 |
Why?
| | Documentation | 1 | 2020 | 194 | 0.140 |
Why?
| | Prospective Studies | 3 | 2021 | 7805 | 0.140 |
Why?
| | Vancomycin | 1 | 2018 | 92 | 0.140 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2017 | 863 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1336 | 0.130 |
Why?
| | Genes, rRNA | 1 | 2017 | 42 | 0.130 |
Why?
| | Streptococcus | 1 | 2017 | 29 | 0.130 |
Why?
| | Perioperative Care | 1 | 2020 | 228 | 0.130 |
Why?
| | Atherectomy, Coronary | 1 | 2017 | 10 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2018 | 74 | 0.130 |
Why?
| | Coronary Stenosis | 1 | 2017 | 38 | 0.130 |
Why?
| | Antiviral Agents | 2 | 1994 | 748 | 0.130 |
Why?
| | Antibodies, Monoclonal | 10 | 2016 | 1456 | 0.130 |
Why?
| | Behavior, Addictive | 1 | 2018 | 89 | 0.130 |
Why?
| | History, 21st Century | 1 | 2018 | 218 | 0.130 |
Why?
| | Homeostasis | 1 | 2021 | 632 | 0.130 |
Why?
| | Antibodies | 8 | 1983 | 399 | 0.130 |
Why?
| | Coronary Occlusion | 1 | 2017 | 20 | 0.130 |
Why?
| | Contrast Media | 1 | 2020 | 476 | 0.130 |
Why?
| | Young Adult | 5 | 2021 | 13727 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 182 | 0.130 |
Why?
| | Data Collection | 1 | 2020 | 655 | 0.130 |
Why?
| | Psychological Trauma | 1 | 2017 | 55 | 0.130 |
Why?
| | Cocaine-Related Disorders | 1 | 2018 | 136 | 0.130 |
Why?
| | Myeloma Proteins | 8 | 1984 | 13 | 0.130 |
Why?
| | Peroxidase | 2 | 1994 | 174 | 0.130 |
Why?
| | Binding Sites, Antibody | 6 | 1988 | 40 | 0.130 |
Why?
| | Population Surveillance | 1 | 2020 | 481 | 0.120 |
Why?
| | Program Evaluation | 3 | 2017 | 919 | 0.120 |
Why?
| | Blood Transfusion | 2 | 2017 | 395 | 0.120 |
Why?
| | Immunoglobulin G | 11 | 1988 | 882 | 0.120 |
Why?
| | Antigens | 11 | 1979 | 349 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2018 | 6270 | 0.120 |
Why?
| | Mice, Inbred Strains | 5 | 1987 | 404 | 0.120 |
Why?
| | Glucose | 1 | 2021 | 1027 | 0.120 |
Why?
| | Comorbidity | 2 | 2018 | 1671 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 233 | 0.120 |
Why?
| | Vascular Calcification | 1 | 2017 | 111 | 0.120 |
Why?
| | Mycoplasma | 1 | 1995 | 5 | 0.120 |
Why?
| | Mycoplasma Infections | 1 | 1995 | 16 | 0.120 |
Why?
| | Femoral Artery | 1 | 2017 | 187 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2366 | 0.120 |
Why?
| | Cross Reactions | 5 | 1988 | 132 | 0.120 |
Why?
| | Antibody Specificity | 10 | 1989 | 183 | 0.120 |
Why?
| | Research Report | 1 | 2016 | 80 | 0.120 |
Why?
| | Medication Errors | 1 | 2016 | 97 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2020 | 645 | 0.120 |
Why?
| | Algorithms | 2 | 2020 | 1764 | 0.110 |
Why?
| | Treatment Outcome | 10 | 2019 | 11216 | 0.110 |
Why?
| | Blood Glucose | 2 | 2024 | 2286 | 0.110 |
Why?
| | Hemorrhage | 2 | 2017 | 788 | 0.110 |
Why?
| | Social Determinants of Health | 1 | 2018 | 275 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1078 | 0.110 |
Why?
| | Prognosis | 2 | 2021 | 4080 | 0.110 |
Why?
| | Saphenous Vein | 1 | 2014 | 36 | 0.110 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 279 | 0.110 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 291 | 0.110 |
Why?
| | Drug-Eluting Stents | 1 | 2014 | 84 | 0.110 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 89 | 0.110 |
Why?
| | Antimicrobial Stewardship | 1 | 2016 | 123 | 0.100 |
Why?
| | Hydrogen Peroxide | 1 | 1995 | 334 | 0.100 |
Why?
| | Infant | 2 | 2018 | 9820 | 0.100 |
Why?
| | Stents | 2 | 2014 | 535 | 0.100 |
Why?
| | Premature Birth | 1 | 2017 | 363 | 0.100 |
Why?
| | Methionine Sulfoximine | 2 | 1990 | 2 | 0.100 |
Why?
| | Patient Selection | 2 | 2016 | 685 | 0.100 |
Why?
| | Lymphocyte Depletion | 2 | 1990 | 136 | 0.100 |
Why?
| | Carmustine | 2 | 1990 | 51 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2017 | 458 | 0.100 |
Why?
| | Child, Preschool | 2 | 2018 | 11511 | 0.100 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7948 | 0.100 |
Why?
| | Overweight | 1 | 2017 | 589 | 0.090 |
Why?
| | Bone Marrow Transplantation | 2 | 1990 | 292 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 477 | 0.090 |
Why?
| | Retrospective Studies | 10 | 2020 | 16447 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2018 | 526 | 0.090 |
Why?
| | Databases, Factual | 4 | 2019 | 1449 | 0.090 |
Why?
| | Immunoglobulin Allotypes | 3 | 1986 | 9 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1866 | 0.090 |
Why?
| | Nitrohydroxyiodophenylacetate | 2 | 1988 | 3 | 0.090 |
Why?
| | Bone Marrow | 2 | 1989 | 298 | 0.090 |
Why?
| | Sex Factors | 1 | 2017 | 2055 | 0.090 |
Why?
| | Rabbits | 15 | 1983 | 664 | 0.090 |
Why?
| | Coronary Disease | 1 | 2013 | 373 | 0.090 |
Why?
| | Military Personnel | 1 | 2018 | 664 | 0.090 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 599 | 0.080 |
Why?
| | Hospitals, Veterans | 3 | 2018 | 255 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2026 | 2929 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 674 | 0.080 |
Why?
| | Plasma Cells | 3 | 1976 | 74 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2765 | 0.080 |
Why?
| | Antigens, Neoplasm | 4 | 1990 | 320 | 0.080 |
Why?
| | Insulin | 1 | 2021 | 2472 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1102 | 0.080 |
Why?
| | Antibodies, Anti-Idiotypic | 3 | 1985 | 50 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4180 | 0.080 |
Why?
| | Prevalence | 4 | 2018 | 2795 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3734 | 0.080 |
Why?
| | Stroke | 1 | 2018 | 1199 | 0.070 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1988 | 20 | 0.070 |
Why?
| | Immunoglobulin Isotypes | 1 | 1988 | 36 | 0.070 |
Why?
| | Hospitalization | 2 | 2016 | 2264 | 0.070 |
Why?
| | Immune Sera | 11 | 1985 | 76 | 0.070 |
Why?
| | Glycoproteins | 1 | 1990 | 354 | 0.070 |
Why?
| | Immunoglobulin M | 6 | 1983 | 284 | 0.070 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 1986 | 85 | 0.070 |
Why?
| | Mice | 30 | 1989 | 17969 | 0.070 |
Why?
| | Animals | 42 | 2021 | 37328 | 0.070 |
Why?
| | Species Specificity | 2 | 1988 | 573 | 0.070 |
Why?
| | Adjuvants, Immunologic | 2 | 1988 | 238 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4599 | 0.070 |
Why?
| | Antibodies, Neoplasm | 2 | 1979 | 33 | 0.070 |
Why?
| | Nitrophenols | 1 | 1987 | 32 | 0.070 |
Why?
| | Cell Line | 6 | 1995 | 2863 | 0.070 |
Why?
| | Immunoglobulins | 7 | 1984 | 162 | 0.070 |
Why?
| | Receptors, Antigen, B-Cell | 5 | 1979 | 132 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2014 | 1030 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 1986 | 72 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 1988 | 467 | 0.060 |
Why?
| | Immunoglobulin Variable Region | 3 | 1983 | 81 | 0.060 |
Why?
| | Immunoelectrophoresis | 11 | 1976 | 13 | 0.060 |
Why?
| | Genes, MHC Class II | 2 | 1983 | 75 | 0.060 |
Why?
| | CpG Islands | 1 | 2025 | 164 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 910 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5948 | 0.060 |
Why?
| | Body Size | 1 | 2025 | 94 | 0.060 |
Why?
| | Anthropometry | 1 | 2025 | 208 | 0.060 |
Why?
| | Workflow | 1 | 2026 | 175 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1939 | 0.050 |
Why?
| | B-Lymphocytes | 3 | 1979 | 857 | 0.050 |
Why?
| | p-Azobenzenearsonate | 1 | 1983 | 5 | 0.050 |
Why?
| | Azo Compounds | 1 | 1983 | 29 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 518 | 0.050 |
Why?
| | Mice, Inbred A | 3 | 1988 | 50 | 0.050 |
Why?
| | Lymphocytes | 3 | 1979 | 390 | 0.050 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 1979 | 23 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 1983 | 207 | 0.050 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2021 | 15 | 0.040 |
Why?
| | Adsorption | 4 | 1975 | 154 | 0.040 |
Why?
| | Kinetics | 6 | 1989 | 1620 | 0.040 |
Why?
| | Diet Surveys | 1 | 2021 | 91 | 0.040 |
Why?
| | Binding, Competitive | 4 | 1983 | 193 | 0.040 |
Why?
| | Acyltransferases | 1 | 2021 | 75 | 0.040 |
Why?
| | Antibody Formation | 5 | 1987 | 295 | 0.040 |
Why?
| | Radiometry | 1 | 2021 | 54 | 0.040 |
Why?
| | Microsomes | 4 | 1975 | 33 | 0.040 |
Why?
| | Lipase | 1 | 2021 | 68 | 0.040 |
Why?
| | Lymph Nodes | 5 | 1985 | 494 | 0.040 |
Why?
| | Immunoglobulin Fab Fragments | 3 | 2016 | 56 | 0.040 |
Why?
| | Neoplasms, Experimental | 4 | 1979 | 174 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 661 | 0.040 |
Why?
| | Protons | 1 | 2021 | 93 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 643 | 0.040 |
Why?
| | Forehead | 1 | 2020 | 5 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1990 | 1791 | 0.040 |
Why?
| | HIV Infections | 1 | 1995 | 2981 | 0.040 |
Why?
| | Patient Readmission | 2 | 2017 | 698 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 343 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2021 | 150 | 0.040 |
Why?
| | Buthionine Sulfoximine | 2 | 1990 | 10 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 86 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 811 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 45 | 0.040 |
Why?
| | Mouth | 1 | 2020 | 88 | 0.040 |
Why?
| | Gene-Environment Interaction | 1 | 2021 | 187 | 0.040 |
Why?
| | Multiple Myeloma | 3 | 1984 | 280 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2020 | 124 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 717 | 0.040 |
Why?
| | Immunoglobulin mu-Chains | 1 | 1979 | 8 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 144 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 1979 | 51 | 0.040 |
Why?
| | Oceania | 1 | 2018 | 5 | 0.040 |
Why?
| | Metabolomics | 1 | 2024 | 702 | 0.040 |
Why?
| | Carrier Proteins | 1 | 1983 | 738 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2019 | 68 | 0.040 |
Why?
| | Child Behavior | 1 | 2021 | 250 | 0.040 |
Why?
| | Drug Synergism | 2 | 1990 | 367 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 855 | 0.040 |
Why?
| | Antigens, Surface | 1 | 1979 | 152 | 0.040 |
Why?
| | Antigens, CD | 2 | 1993 | 537 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 108 | 0.040 |
Why?
| | Quality Improvement | 2 | 2018 | 1241 | 0.040 |
Why?
| | Teratoma | 1 | 1979 | 121 | 0.040 |
Why?
| | Peptides | 4 | 2016 | 971 | 0.040 |
Why?
| | Cattle | 1 | 2021 | 982 | 0.040 |
Why?
| | Erythrocytes | 3 | 1989 | 698 | 0.040 |
Why?
| | Genes, Regulator | 1 | 1978 | 36 | 0.040 |
Why?
| | Mice, Inbred C57BL | 9 | 1988 | 5866 | 0.040 |
Why?
| | Skin | 1 | 2023 | 760 | 0.030 |
Why?
| | Mice, Inbred C3H | 4 | 1988 | 255 | 0.030 |
Why?
| | Glutathione | 2 | 1990 | 361 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2020 | 267 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1137 | 0.030 |
Why?
| | North America | 1 | 2018 | 304 | 0.030 |
Why?
| | Europe | 1 | 2018 | 408 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2017 | 24 | 0.030 |
Why?
| | Punctures | 1 | 2017 | 40 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 367 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 1989 | 77 | 0.030 |
Why?
| | Transfusion Reaction | 1 | 2017 | 62 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 1990 | 408 | 0.030 |
Why?
| | Fibrosarcoma | 1 | 1976 | 21 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 859 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 321 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 189 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 86 | 0.030 |
Why?
| | Drug Labeling | 1 | 2016 | 38 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 755 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 237 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2016 | 61 | 0.030 |
Why?
| | Adolescent Behavior | 1 | 2021 | 538 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1037 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 453 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 330 | 0.030 |
Why?
| | Risk-Taking | 1 | 2018 | 341 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 784 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 6 | 1993 | 333 | 0.030 |
Why?
| | Fluorescence | 1 | 1995 | 161 | 0.030 |
Why?
| | Device Removal | 1 | 2016 | 141 | 0.030 |
Why?
| | Immunodiffusion | 7 | 1974 | 12 | 0.030 |
Why?
| | Cell Survival | 2 | 1990 | 1123 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2021 | 1144 | 0.030 |
Why?
| | Bioprosthesis | 1 | 2014 | 39 | 0.030 |
Why?
| | Phytohemagglutinins | 1 | 1994 | 29 | 0.030 |
Why?
| | HIV Core Protein p24 | 1 | 1994 | 32 | 0.030 |
Why?
| | Immune Tolerance | 3 | 1993 | 373 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1057 | 0.030 |
Why?
| | Angina, Unstable | 1 | 2014 | 78 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1994 | 168 | 0.030 |
Why?
| | Catalase | 1 | 1994 | 134 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1979 | 0.030 |
Why?
| | Health Promotion | 1 | 2020 | 749 | 0.030 |
Why?
| | Metals | 1 | 2014 | 140 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 359 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1505 | 0.030 |
Why?
| | Inflammation | 1 | 2024 | 2840 | 0.020 |
Why?
| | Polystyrenes | 1 | 1993 | 38 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2018 | 577 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1993 | 75 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1993 | 97 | 0.020 |
Why?
| | Lymphokines | 1 | 1993 | 131 | 0.020 |
Why?
| | Fibronectins | 1 | 1993 | 135 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 335 | 0.020 |
Why?
| | CD4 Antigens | 1 | 1993 | 141 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1546 | 0.020 |
Why?
| | Mental Health | 1 | 2018 | 756 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2069 | 0.020 |
Why?
| | Immunization, Passive | 2 | 1989 | 88 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 849 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1820 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 783 | 0.020 |
Why?
| | Heparin | 1 | 1993 | 254 | 0.020 |
Why?
| | Epitopes | 4 | 1979 | 476 | 0.020 |
Why?
| | Acrylamides | 1 | 1972 | 67 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 2 | 1989 | 221 | 0.020 |
Why?
| | CD52 Antigen | 1 | 1990 | 3 | 0.020 |
Why?
| | Blood Proteins | 1 | 1973 | 244 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1807 | 0.020 |
Why?
| | Thymus Neoplasms | 1 | 1990 | 26 | 0.020 |
Why?
| | Thymoma | 1 | 1990 | 36 | 0.020 |
Why?
| | Mice, Inbred DBA | 2 | 1988 | 198 | 0.020 |
Why?
| | Isoelectric Focusing | 2 | 1988 | 30 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 393 | 0.020 |
Why?
| | Proteins | 2 | 1993 | 1007 | 0.020 |
Why?
| | Virus Replication | 1 | 1993 | 533 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2808 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1990 | 448 | 0.020 |
Why?
| | Dinitrophenols | 1 | 1988 | 8 | 0.020 |
Why?
| | Trinitrobenzenes | 1 | 1988 | 14 | 0.020 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 9 | 0.020 |
Why?
| | Rats, Nude | 1 | 1988 | 23 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 1990 | 959 | 0.020 |
Why?
| | Esterases | 3 | 1968 | 9 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 3 | 1975 | 50 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 1969 | 233 | 0.020 |
Why?
| | Oxidative Stress | 1 | 1995 | 1327 | 0.020 |
Why?
| | Hybridomas | 2 | 1993 | 233 | 0.020 |
Why?
| | Lymphoma | 1 | 1990 | 228 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 1989 | 316 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 802 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1989 | 1059 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2020 | 2831 | 0.020 |
Why?
| | Immunotherapy | 2 | 1989 | 641 | 0.020 |
Why?
| | Sheep | 4 | 1981 | 868 | 0.020 |
Why?
| | Rats | 7 | 1988 | 5556 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 1993 | 2146 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1988 | 319 | 0.020 |
Why?
| | Isoelectric Point | 1 | 1986 | 23 | 0.020 |
Why?
| | Heart Failure | 1 | 2020 | 2096 | 0.020 |
Why?
| | Electrophoresis | 4 | 1968 | 31 | 0.020 |
Why?
| | Chromium Radioisotopes | 1 | 1986 | 4 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1989 | 571 | 0.020 |
Why?
| | Abortion, Veterinary | 1 | 1986 | 2 | 0.020 |
Why?
| | Methods | 2 | 1979 | 68 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1969 | 353 | 0.010 |
Why?
| | Fetal Resorption | 1 | 1985 | 2 | 0.010 |
Why?
| | Fetal Death | 1 | 1985 | 59 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5222 | 0.010 |
Why?
| | Neoplasm Transplantation | 4 | 1984 | 251 | 0.010 |
Why?
| | Precipitin Tests | 2 | 1975 | 96 | 0.010 |
Why?
| | Cell Nucleus | 4 | 1968 | 607 | 0.010 |
Why?
| | Immunoglobulin Constant Regions | 1 | 1983 | 7 | 0.010 |
Why?
| | Phenylalanine | 1 | 1963 | 66 | 0.010 |
Why?
| | H-2 Antigens | 2 | 1986 | 115 | 0.010 |
Why?
| | Acetates | 1 | 1963 | 82 | 0.010 |
Why?
| | Cells, Cultured | 2 | 1990 | 4149 | 0.010 |
Why?
| | Interferon Type I | 1 | 1984 | 140 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1969 | 741 | 0.010 |
Why?
| | Chromatography | 2 | 1973 | 22 | 0.010 |
Why?
| | Perfusion | 1 | 1963 | 226 | 0.010 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1983 | 134 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1981 | 48 | 0.010 |
Why?
| | Clone Cells | 2 | 1979 | 267 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1981 | 54 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1993 | 51 | 0.010 |
Why?
| | Research | 1 | 1963 | 434 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1979 | 164 | 0.010 |
Why?
| | Papain | 1 | 1979 | 3 | 0.010 |
Why?
| | Thymus Gland | 1 | 1979 | 316 | 0.010 |
Why?
| | Genes | 1 | 1978 | 229 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1978 | 288 | 0.010 |
Why?
| | Immunosorbent Techniques | 1 | 1976 | 18 | 0.010 |
Why?
| | Spleen | 3 | 1979 | 512 | 0.010 |
Why?
| | Sarcoma, Experimental | 1 | 1976 | 6 | 0.010 |
Why?
| | Mitochondria | 1 | 1963 | 962 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1976 | 25 | 0.010 |
Why?
| | Vaccination | 1 | 1985 | 1468 | 0.010 |
Why?
| | Glutaral | 1 | 1975 | 15 | 0.010 |
Why?
| | Antigens, Heterophile | 1 | 1975 | 5 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1976 | 152 | 0.010 |
Why?
| | Immunoassay | 1 | 1976 | 110 | 0.010 |
Why?
| | Cytoplasm | 1 | 1976 | 267 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1976 | 381 | 0.010 |
Why?
| | Cell Differentiation | 2 | 1974 | 1983 | 0.010 |
Why?
| | Antibody-Producing Cells | 1 | 1974 | 30 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1974 | 128 | 0.010 |
Why?
| | Globulins | 1 | 1973 | 1 | 0.010 |
Why?
| | Chloroform | 1 | 1973 | 2 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1976 | 439 | 0.010 |
Why?
| | Immunoglobulin Fragments | 1 | 1973 | 11 | 0.010 |
Why?
| | Thermolysin | 1 | 1993 | 4 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1973 | 6 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1983 | 2600 | 0.010 |
Why?
| | Absorption | 1 | 1993 | 60 | 0.010 |
Why?
| | CD57 Antigens | 1 | 1993 | 18 | 0.010 |
Why?
| | Chick Embryo | 1 | 1973 | 133 | 0.010 |
Why?
| | Solubility | 1 | 1973 | 239 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 1993 | 206 | 0.010 |
Why?
| | Microspheres | 1 | 1993 | 140 | 0.010 |
Why?
| | Hydrolysis | 1 | 1993 | 195 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1993 | 138 | 0.010 |
Why?
| | Chickens | 1 | 1973 | 189 | 0.010 |
Why?
| | Immunochemistry | 1 | 1972 | 12 | 0.010 |
Why?
| | Immunologic Techniques | 1 | 1972 | 38 | 0.010 |
Why?
| | Animals, Newborn | 1 | 1974 | 866 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1972 | 172 | 0.010 |
Why?
| | Cell Membrane | 1 | 1975 | 704 | 0.010 |
Why?
| | Muramidase | 1 | 1972 | 66 | 0.010 |
Why?
| | Leukocytes | 1 | 1973 | 293 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1972 | 144 | 0.010 |
Why?
| | Cholinesterases | 2 | 1968 | 9 | 0.010 |
Why?
| | Deoxyribonucleases | 2 | 1968 | 24 | 0.010 |
Why?
| | Aldehydes | 1 | 1972 | 146 | 0.010 |
Why?
| | L-Lactate Dehydrogenase | 2 | 1968 | 113 | 0.010 |
Why?
| | Lipoproteins | 1 | 1971 | 162 | 0.010 |
Why?
| | Blotting, Western | 1 | 1993 | 1220 | 0.010 |
Why?
| | Protein Conformation | 1 | 1993 | 939 | 0.000 |
Why?
| | Endoplasmic Reticulum | 1 | 1971 | 262 | 0.000 |
Why?
| | Ethanol | 1 | 1973 | 627 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1993 | 2911 | 0.000 |
Why?
| | Protein Binding | 1 | 1993 | 2233 | 0.000 |
Why?
| | Liver Diseases | 1 | 1969 | 301 | 0.000 |
Why?
| | Enzymes | 1 | 1966 | 65 | 0.000 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1986 | 173 | 0.000 |
Why?
| | Fetal Viability | 1 | 1985 | 3 | 0.000 |
Why?
| | Genetic Variation | 1 | 1970 | 993 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1985 | 55 | 0.000 |
Why?
| | Pronase | 1 | 1981 | 5 | 0.000 |
Why?
| | Rosette Formation | 1 | 1981 | 14 | 0.000 |
Why?
| | Trypsin | 1 | 1981 | 73 | 0.000 |
Why?
| | Contact Inhibition | 2 | 1970 | 5 | 0.000 |
Why?
| | Culture Techniques | 2 | 1970 | 74 | 0.000 |
Why?
| | Lymphocyte Activation | 1 | 1985 | 1136 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1985 | 716 | 0.000 |
Why?
| | Ascitic Fluid | 1 | 1979 | 15 | 0.000 |
Why?
| | Microscopy, Electron | 2 | 1970 | 414 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 367 | 0.000 |
Why?
| | Epithelium | 2 | 1970 | 311 | 0.000 |
Why?
| | beta-Galactosidase | 1 | 1979 | 78 | 0.000 |
Why?
| | Cell Cycle | 1 | 1981 | 601 | 0.000 |
Why?
| | Placenta | 1 | 1985 | 764 | 0.000 |
Why?
| | Fibroblasts | 2 | 1970 | 1018 | 0.000 |
Why?
| | Neuraminic Acids | 1 | 1972 | 1 | 0.000 |
Why?
| | Neuraminidase | 1 | 1972 | 25 | 0.000 |
Why?
| | Vibrio cholerae | 1 | 1972 | 14 | 0.000 |
Why?
| | Densitometry | 1 | 1972 | 38 | 0.000 |
Why?
| | Ultracentrifugation | 1 | 1972 | 51 | 0.000 |
Why?
| | Microsomes, Liver | 1 | 1972 | 83 | 0.000 |
Why?
| | Leukemia Virus, Murine | 1 | 1970 | 18 | 0.000 |
Why?
| | Intestines | 1 | 1972 | 355 | 0.000 |
Why?
|
|
Stanislawski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|